Cell and gene therapies (CGTs) are progressively entering into clinical practice in different parts of the world. The International Society for Cell & Gene Therapy (ISCT), a global scientific society, has been committed since 1992 to supporting and developing knowledge on clinical applications of CGTs. Considering the number of products that have been progressively approved and, in some cases, withdrawn in recent years, the ISCT would like to present a brief annual report on CGTs with marketing authorization (MA) in different regions. This article reflects the dynamic momentum around authorized CGTs coinciding with the parallel increase of unproven approaches where cells are delivered without appropriate and rigorous scientific and regulatory assessment and authorization. This is intended to be a living document with a yearly update linked to a dedicated section of the ISCT website for faster adjustments. The aim is to ultimately inform, by periodic snapshots, the scientific community, healthcare stakeholders and patient associations on authorized CGT products as a way to increase communication around the approved therapeutic approaches charged with heightened expectations.
Introduction
The International Society for Cell & Gene Therapy (ISCT) is committed to translating cellular therapy into safe and effective treatments to improve patients' lives while minimizing and balancing risks for patients. Being aware that many unproven or insufficiently proven cell-based treatments are commercially available for hopeful individuals seeking cures or health improvement for a variety of conditions, the ISCT created the ISCT Presidential Task Force (PTF) on the Use of Unproven Cellular Therapies (UCT) in 2014. The PTF-UCT strives to characterize unproven cellular interventions and promote safe and effective practices worldwide [1, 2] .
In line with the above goals, the PTF-UCT has launched several initiatives including providing updated information on approved cellular therapies. For a list of PTF-UCTÀauthored resources visit http://www.celltherapysociety.org/page/UCT. In this document the PTF-UCT has summarized cell, tissue and gene medicinal products authorized for commercialization by regions/countries, to help patients seeking safe and effective treatments. We have not included any products that are categorized as medical devices, even if they are cell-based. If a patient lives in one of the regions/countries included in the document and a healthcare professional or a business is offering a cell-based treatment not listed, they should ask whether they are going to receive the treatment as part of a clinical trial. If not, the ISCT recommends asking for more information about the "regulatory status" of the treatment they are going to receive to make an informed decision.
Definitions and principles
Human cellÀ or tissue-based products are highly heterogeneous and regulatory authorities will always apply their rulings on a case-by-case basis. Nevertheless, at present, most of the cell-and tissue-based products are considered biological medicinal products in those countries with more developed regulatory structures. The development of safe and effective "proven" cell therapies requires testing these medicinal products according to some general principles [3] . Before administration into humans, both biological activity and toxicity of the investigational medicinal product must be tested in relevant animal model(s). Researchers must then seek approval of an institutional review board (IRB) for all centers involved in the clinical trial as well as an authorization from the national regulatory agencies of the countries where patients will be recruited, irrespective of their nationalities. The sponsor's duties also include ensuring: (i) that there is an insurance policy in place to cover any liability, (ii) that recruitment of subjects is done after appropriate informed consent and (iii) that medicinal product batches for release conform to specifications. If the regulatory bodies determine that quality, safety and efficacy of a cell-or tissue-based medicinal product are sufficiently established through successful clinical phases (clinical trial phase 1, 2 and 3), then the next step is to apply for marketing authorization (MA). After that, the company that holds the MA can commercialize the medicinal product in the countries in which the product has been granted MA. In some cases, MA is provisional and post-marketing surveillance studies are required. Of note, some countries permit exceptions to this authorization rule depending on the nature of the medicinal product, be it industrial or otherwise. In any case, the use of a medicinal product has to be supervised by a regulatory body.
Identified cell and gene therapies with MA
We have identified and listed cell and gene therapies (CGTs) with MA based on available information, considering as a source of trustworthy information the regulatory body web resources, official press release by the interested companies or other source of data as indicated in Tables IÀX where countries/ regions are listed in alphabetical order. The list has been updated as of September 15, 2018, unless otherwise specified.
In Figure 1 , we present the distribution of authorized CGT products by region. In addition, we have listed (Table XI) the CGT approaches that have received a Regenerative Medicine Advanced Therapy (RMAT) designation by the United States Food and Drug Administration (USFDA) [4] but have not been approved as of September 2018. In Figure 2 , we have categorized CGT products with MA worldwide in three different ways, namely, by product, therapy and disease type. Finally, in Figure 3 we present CGT products according to the year in which they received MA.
Several products are currently available in different regions but have the same MA holder (YESCARTA, KYMRIAH, IMLYGIC, RMS Ossron/OSSGROW and Chondron/CARTIGROW). These products are taken into account only once in Figures 2 and 3 , leading to a total number of 44 unique products.
Discussion and conclusions
The goal of this article is to provide a quick reference for anyone interested in a snapshot, to be updated annually, of the CGT landscape worldwide. This list may not be exhaustive and additional CGT products We have identified 44 unique products, 37 of them are cell and tissue therapies (84%) and mainly autologous (55%) ( Figure 2 ). As far as targeted diseases are concerned, more than one third of the products are intended for the treatment of oncological or hematologic diseases.
As shown in Figure 3 , the number of products with MA has increased in recent years. For example, those authorized from 2015 to September 2018 represent 45%. Unfortunately, there has been a parallel increase in the number of businesses offering unproven and unlicensed cell-based interventions [5, 6] .
Even though the distribution of authorized CGTs shows important differences among countries or regions, it is not our intention to debate the complex financial, societal and scientific reasons behind these differences or the impact of different regulatory systems on the number of marketed products. As members of the ISCT PTF-UCT, our main objective is to help patients make informed decisions before receiving a cell or gene treatment so that they can avoid being exposed to unproven and unlicensed cell interventions. For that purpose, we aim to provide a reliable, up-to-date resource where patients or professionals can check whether a cell or gene therapy has been approved by a regulatory/medicine agency.
As mentioned before, the ISCT recommends asking for information about the "regulatory status" of the treatment patients are going to receive to make an informed decision. This is particularly relevant for patients living in one of the regions/countries included in the document who seek safe and effective treatments, should a healthcare professional or a business offer a CGT that is neither listed nor part of a clinical trial.
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